We are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. (Incorporated in Delaware)

Our product candidate, cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC. There is significant unmet need for treatments in these patients given the limitations of currently approved therapies and patient reluctance to undergo radical cystectomy, or the complete removal of the bladder.

We are evaluating the safety and efficacy of cretostimogene as monotherapy in BOND-003, our ongoing Phase 3 clinical trial in high-risk BCG-unresponsive NMIBC patients. We have completed enrollment for this trial, reported interim data in November 2023 and expect to report topline data by the end of 2024. If successful, we believe that this trial could serve as the basis for a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA).

We are also evaluating the use of cretostimogene when administered to this same patient population in combination with FDA-approved pembrolizumab in CORE-001, our ongoing Phase 2 clinical trial. Moreover, we intend to assess the safety and efficacy of cretostimogene in treating a range of other bladder cancer indications as an alternative to BCG therapy and in patients who are not categorized as BCG-unresponsive, including our second Phase 3 clinical trial, PIVOT-006, evaluating adjuvant cretostimogene in intermediate-risk NMIBC patients following transurethral resection of the bladder tumor (TURBT). We believe cretostimogene, if approved, has the potential to serve as first-line therapy, thereby alleviating the current need to prioritize treatment recipients and ration administration of BCG, given its significant market shortage.

**Note: Net loss and revenue figures are for the 12 months that ended Sept. 30, 2023.

*Note: A 1-for-9.535 reverse stock split became effective on Jan. 16, 2024.

(Note: CG Oncology, Inc. upsized its IPO at pricing – to 20.0 million shares – up from its recently increased size of 17.0 million shares – and priced the IPO at $19.00 – $1.00 above the top of its range – to raise $380.0 million on Wednesday night, Jan. 24, 2024. Background: CG Oncology increased its IPO’s size in an S-1/A filing on Jan. 23, 2024, by raising the number of shares to 17.0 million – up from 11.8 million  originally – and keeping the price range at $16.00 to $18.00. Background: CG Oncology, Inc. filed an S-1/A on Jan. 18, 2024, disclosing terms for its IPO: 11.8 million shares at a price range of $16.00 to $18.00 to raise $200.6 million. Background: CG Oncology, Inc. filed its S-1 on Jan. 2, 2024, without disclosing terms for its IPO. The Street estimates the IPO proceeds at $100 million, a placeholder figure. The company submitted confidential IPO documents to the SEC on Oct. 27, 2023.)